Tonix Pharma’s Potential PTSD Cure: A Game-Changer?

Tonix Pharmaceuticals Receives FDA Clearance for OASIS Trial

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. The clearance allows the company to proceed with a Phase 2 trial evaluating the efficacy of TNX-102 SL in treating acute stress reactions (ASR) and reducing the onset of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) following traumatic events.